ArticlePloS one2015
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Neuropsychiatric systemic lupus erythematosus subtypes identified by unsupervised clustering: A single-center cohort study.Rheumatology and immunology research · 2026Article
- Successful Treatment of a Patient with Neuropsychiatric Lupus and Triple Positive Antiphospholipid Syndrome with Chronic Isolated Seizure: A Case Report.Acta medica Philippina · 2025Article
- Article
- Article
- Diagnosis and Management of Pediatric Neuropsychiatric Systemic Lupus Erythematosus: An Update.Paediatric drugs · 2024Review
- Prediction model for developing neuropsychiatric systemic lupus erythematosus in lupus patients.Clinical rheumatology · 2024Article
- Pattern of disease expression in SLE patients with antiphospholipid antibodies: data from Indian Systemic Lupus Erythematosus Inception cohort (INSPIRE).Rheumatology international · 2024Article
- Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus.Lupus science & medicine · 2024Article
- Epilepsy, Immunity and Neuropsychiatric Disorders.Current neuropharmacology · 2023Review
- Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade.Brain sciences · 2022Review
- Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.Journal of neuroinflammation · 2021Review
- Article
- Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China.Journal of immunology research · 2021Article
- Systemic lupus erythematosus presenting with status epilepticus and acute cardiomyopathy with acute heart failure: case report.The Egyptian journal of neurology, psychiatry and neurosurgery · 2020Article
- The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients.Clinical rheumatology · 2019Article
- Application value of iterative reconstruction with CTA to intractable headache patients.Experimental and therapeutic medicine · 2018Article
- The role of inflammation in the development of epilepsy.Journal of neuroinflammation · 2018Review
- [Causes of stroke among young people: role of the internist].The Pan African medical journal · 2018Article
- Is There an Increased Risk for Ischemic Stroke in Patients with Multiple Sclerosis, and If So, Should Preventive Treatment Be Considered?Frontiers in neurology · 2016Article
- The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus.BMC genetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important aPL antigen, are thought to play a role in some forms of NPSLE. As of yet, their specific roles in NPSLE manifestations remain to be elucidated. METHODOLOGY/PRINCIPAL
findings57 SLE patients (53 women) were assessed for LA, aCL and anti-β2GPI twice, to determine persistent positivity. All patients were examined by neurology and psychiatry specialists. 69 healthy subjects were assessed as controls. NPSLE was diagnosed in 74% of patients. Headaches were the most prevalent manifestation of NPSLE (39%), followed by cerebrovascular disease (CVD) (23%), depressive disorders (19.0%), and seizures (14%). NPSLE and non-NPSLE patients showed comparable SLE activity and corticosteroid use. In 65% of patients neuropsychiatric manifestations preceded SLE diagnosis. aPL profiles of NPSLE patients and non-NPSLE patients were similar. Headaches and ischemic stroke were independently associated with anti-β2GPI-IgM (OR=5.6; p<0.05), and seizures were linked to anti-β2GPI-IgG (OR=11.3; p=0.01).
conclusionsIn SLE patients, neuropsychiatric manifestations occur frequently and early, often before the disease is diagnosed. Autoantibodies to β2GPI are linked to non-specific headaches, ischemic stroke and seizures, and show a better predictive value than aCL and LA. These findings may help to improve the diagnosis of NPSLE and should prompt further studies to characterize the role of anti-β2GPI in the pathogenesis of this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.